POLBF News and Press, Poolbeg Pharma plc Ord GBP 0.0002 From 02/08/24

(NewsDirect) Poolbeg Pharma PLC's newly appointed Vice President of Clinical Operations Laura Maher joined Proactive's Stephen Gunnion to discuss her role at the company. Maher detailed her responsibilities at Poolbeg, emphasising her leadership in developing and managing clinical pro...

Further Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Market opportunity estimated to be greater than US$1 billion Key highlights - Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model - Data ...

Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV drug candidates with the highest probability of success prioritised LONDON, UK / ACCESSWIRE / December 20, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a biopharmaceu...

POLB 001 - targeting Cytokine Release Syndrome (CRS) associated with cancer immunotherapies LONDON, UK / ACCESSWIRE / December 11, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of in...

LONDON, UK / ACCESSWIRE / November 30, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change to its B...

Further enhancement of the patent portfolio LONDON, UK / ACCESSWIRE / November 21, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a hig...

POLB 001 - a potential blockbuster immunomodulator LONDON, UK / ACCESSWIRE / November 16, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases wit...

Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma Poolbeg team boosted by highly experienced executives with track record of success LONDON, UK / ACCESSWIRE / November 9, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a clinical...

Potential to address cancer treatment related Cytokine Release Syndrome LONDON, UK / ACCESSWIRE / November 3, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces ...

(NewsDirect) Proactive Research Analyst Daniel Appiah speaks to Thomas Warner at the London Studio after publishing a new research note on clinical-stage biopharmaceutical company Poolbeg Pharma. Appiah starts by explaining the scale of the opportunity that Poolbeg is pursuing with it...